Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial

• Egile Nagusiak: Kenji Kabashima (Egilea), Takayo Matsumura (Egilea), Hiroshi Komazaki (Egilea), Makoto Kawashima (Egilea), The Nemolizumab-JP01 Study Group (Egilea)
• Formatua: Liburua
• Argitaratua: Adis, Springer Healthcare, 2023-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Introduction Atopic dermatitis (AD), with its signs and symptoms of pruritus, dryness, and erythema, severely reduces the quality of life (QOL) of affected patients. We investigated the impact of nemolizumab 60 mg on QOL in Japanese patients aged ≥ 13 years with AD and inadequately controll...